Pharmacokinetic properties of MH84, a γ-secretase modulator with PPARγ agonistic activity

Journal of Pharmaceutical and Biomedical Analysis

Volumn 102, Issue , 2015, Pages 417-424

  Pellowska, M ^a   Stein, C ^a   Pohland, M ^a   Merk, D ^a   Klein, J ^a   Eckert, G P ^a   Schubert Zsilavecz, M ^a   Wurglics, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; CNS bioavailability; Pharmacokinetics; PPAR agonist; Secretase modulator

Indexed keywords

FORMIC ACID; GAMMA SECRETASE; METHANOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; UNCLASSIFIED DRUG; [2 [[4,6 BIS[4 (TRIFLUOROMETHYL)PHENETHOXY]PYRIMIDIN 2 YL]THIO]HEXANOIC ACID]; AMYLOID PRECURSOR PROTEIN SECRETASES; CAPROATES; PPAR GAMMA; PYRIMIDINES;

ALZHEIMER DISEASE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SEPARATION TECHNIQUE; TIME OF FLIGHT MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS; AGONISTS; ANIMALS; CHEMISTRY; CHROMATOGRAPHY, LIQUID; METABOLISM; METHODS; MICE; SWINE; TANDEM MASS SPECTROMETRY;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CAPROATES; CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; MICE; PPAR GAMMA; PYRIMIDINES; SWINE; TANDEM MASS SPECTROMETRY;

EID: 84909619993     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.10.001     Document Type: Article

References (25)

1. Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39:333-340.
2. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.-X. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011, 225:54-62.
3. Hieke M., Ness J., Steri R., Dittrich M., Greiner C., Werz O., Baumann K., Schubert-Zsilavecz M., Weggen S., Zettl H. Design, synthesis, and biological evaluation of a novel class of γ-secretase modulators with PPARγ activity. J. Med. Chem. 2010, 53:4691-4700.
4. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
5. Golde T.E., Cai X.D., Shoji M., Younkin S.G. Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer's disease. Ann. N. Y. Acad. Sci. 1993, 695:103-108.
6. Cernescu M., Stark T., Kalden E., Kurz C., Leuner K., Deller T., Göbel M., Eckert G.P., Brutschy B. Laser-induced liquid bead ion desorption mass spectrometry: an approach to precisely monitor the oligomerization of the β-amyloid peptide. Anal. Chem. 2012, 84:5276-5284.
7. Marshall K.E., Marchante R., Xue W.-F., Serpell L.C. The relationship between amyloid structure and cytotoxicity. Prion 2014, 8.
8. de Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
9. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
10. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
11. Rossner S., Sastre M., Bourne K., Lichtenthaler S.F. Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog. Neurobiol. 2006, 79:95-111.
12. Yamanaka M., Ishikawa T., Griep A., Axt D., Kummer M.P., Heneka M.T. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 2012, 32:17321-17331.
13. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
14. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
15. Arnaud L., Robakis N.K., Figueiredo-Pereira M.E. It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener. Dis. 2006, 3:313-319.
16. Wood W.G., Li L., Müller W.E., Eckert G.P. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J. Neurochem. 2014, 129:559-572.
17. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118:4002-4013.
18. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 2001, 7:161-171.
19. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., Paul S.M., Holtzman D.M. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118:671-682.
20. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
21. Frölich L., Blum-Degen D., Riederer P., Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann. N. Y. Acad. Sci. 1999, 893:290-293.
22. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.-W., Kovacina K.S., Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 2003, 162:313-319.
23. Quan Q., Wang J., Li X., Wang Y. Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPAR(and IDE expression in the hippocampus of a rat model of Alzheimer's disease. PLoS ONE 2013, 8:e59155.
24. FDA, www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
25. Zhang Y., Huo M., Zhou J., Xie S., Solver P.K. An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 2010, 99:306-314.